CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Welcome to Capital.com. The products and services listed on this website are not available to US residents.

Trade Olema Pharmaceuticals, Inc. - OLMA CFD

6.06
5.57%
0.08
Low: 5.64
High: 6.15
Swap Long:
95 %
Swap Short:
5 %
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon: 14:30 - 21:00

Tue: 14:30 - 18:00

Thu - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.08
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023374 %
Charges from full value of position ($-0.23)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
-0.023374%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.001151 %
Charges from full value of position ($0.01)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
0.001151%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 50.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 5.74
Open 5.75
1-Year Change -57.41%
Day's Range 5.64 - 6.15
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 20, 2024 6.06 0.40 7.07% 5.66 6.17 5.64
Dec 19, 2024 5.74 -0.03 -0.52% 5.77 5.95 5.52
Dec 18, 2024 5.80 -0.37 -6.00% 6.17 6.17 5.58
Dec 17, 2024 6.10 -0.14 -2.24% 6.24 6.46 6.04
Dec 16, 2024 6.36 -0.41 -6.06% 6.77 6.79 6.23
Dec 13, 2024 6.69 0.10 1.52% 6.59 6.70 6.20
Dec 12, 2024 6.67 -1.62 -19.54% 8.29 8.30 6.46
Dec 11, 2024 8.36 -1.21 -12.64% 9.57 9.57 8.18
Dec 10, 2024 9.60 0.09 0.95% 9.51 9.69 8.82
Dec 9, 2024 9.41 -0.87 -8.46% 10.28 10.48 9.39
Dec 6, 2024 10.42 0.09 0.87% 10.33 10.89 10.07
Dec 5, 2024 10.24 0.23 2.30% 10.01 10.68 9.89
Dec 4, 2024 10.05 0.33 3.40% 9.72 10.25 9.72
Dec 3, 2024 9.96 -0.17 -1.68% 10.13 10.13 9.82
Dec 2, 2024 10.18 -0.40 -3.78% 10.58 10.58 9.47
Nov 29, 2024 10.09 0.21 2.13% 9.88 10.31 9.88
Nov 27, 2024 10.09 0.53 5.54% 9.56 10.33 9.45
Nov 26, 2024 9.65 0.88 10.03% 8.77 9.92 8.42
Nov 25, 2024 8.86 -0.11 -1.23% 8.97 9.37 8.70
Nov 22, 2024 8.73 0.89 11.35% 7.84 8.85 7.84

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group

680K+

Traders

101K+

Active clients monthly

$215B+

Monthly trading volume

$46M+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
Leverage
2:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Olema Pharmaceuticals, Inc. Company profile

About Olema Pharmaceuticals Inc

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. It was designed based on a structural understanding of the ER. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including a breast cancer brain metastasis model. It’s been ongoing Phase 1/2 clinical trial, and in Phase 1b combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Olema Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders increased from $24M to $71.1M. Higher net loss reflects Research and development increase from $11.7M to $41.8M (expense), Stock-based Compensation in R&D increase from $2M to $9.3M (expense), General and administrative - Balancing increase from $6.7M to $13.8M (expense).

Industry: Biotechnology & Medical Research (NEC)

780 Brannan Street
SAN FRANCISCO
CALIFORNIA 94103
US

People also watch

ETH/USD

3,530.19 Price
+2.670% 1D Chg, %
Swap short:
95 %
Swap long:
5 %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

US100

21,269.40 Price
+0.710% 1D Chg, %
Swap short:
95 %
Swap long:
5 %
Long position overnight fee -0.0234%
Short position overnight fee 0.0012%
Overnight fee time 22:00 (UTC)
Spread 7.0

XRP/USD

2.36 Price
+4.610% 1D Chg, %
Swap short:
95 %
Swap long:
5 %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01175

BTC/USD

98,596.55 Price
+2.100% 1D Chg, %
Swap short:
95 %
Swap long:
5 %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading